


CLAIMS

1. A compound selected from the group consisting of

compounds of formula (I):



wherein

R¹, R², R³ and R⁴ are independently selected from hydrogen, halogen, hydroxy, alkyl, cycloalkyl, arylalkyl, aryl, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, nitro, cyano, alkoxycarbonyl, aryloxycarbonyl, mono- and di-alkylaminocarbonyl, alkylcarbonylamino, carboxy and heterocyclyl, or R³ and R⁴ form together a -CH₂-CH₂-CH₂- group;

with the proviso that at least one of R¹, R², R³ and R⁴ is not hydrogen;

R⁵ is hydrogen, alkyl or cycloalkyl;

R⁶ is hydrogen, alkyl, cycloalkyl, hydroxyalkyl or alkoxyalkyl; and

R⁷ is hydrogen, halogen, alkyl, cycloalkyl, hydroxyalkyl, carboxyalkyl, carbamoylalkyl, alkoxycarbonylalkyl, aryloxycarbonylalkyl, formyl, alkylcarbonyl, alkoxy or alkylthio;

pharmaceutically acceptable salts of compounds of formula (I);

pharmaceutically acceptable solvates of compounds of formula (I); and

pharmaceutically acceptable esters of compounds of formula (I).

2. The compound according to claim 1, wherein

R¹, R², R³ and R⁴ are independently selected from hydrogen, halogen, hydroxy, alkyl, cycloalkyl, arylalkyl, aryl, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino,

nitro, cyano, alkoxycarbonyl, aryloxycarbonyl, mono- and di-alkylaminocarbonyl, alkylcarbonylamino, carboxy or heterocyclyl;
with the proviso that at least one of the moieties R^1 , R^2 , R^3 and R^4 is not hydrogen; and R^6 is alkyl or cycloalkyl.

3. The compound according to claim 1, wherein R^1 , R^2 , R^3 and R^4 are independently selected from hydrogen, halogen, hydroxy, alkyl, cycloalkyl, arylalkyl, aryl, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, nitro, cyano, alkoxycarbonyl, aryloxycarbonyl, mono- and di-alkylaminocarbonyl, alkylcarbonylamino, carboxy or heterocyclyl;
with the proviso that at least one of the moieties R^1 , R^2 , R^3 and R^4 is not hydrogen; and R^6 is alkyl or hydroxyalkyl.

4. The compound according to claim 3, wherein R^6 is methyl.

5. The compound according to claim 3, wherein R^5 is hydrogen.

6. The compound according to claim 3, wherein R^7 is hydrogen, alkyl or alkoxy.

7. The compound according to claim 6, wherein R^7 is hydrogen or methyl.

8. The compound according to claim 1, wherein R^1 , R^2 , R^3 and R^4 are independently selected from hydrogen, halogen, alkyl, haloalkyl, haloalkoxy and cyano or R^3 and R^4 form together a $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ group.

9. The compound according to claim 8, wherein R^1 , R^2 , R^3 and R^4 are independently selected from hydrogen, halogen, alkyl, trifluoromethyl and cyano.


10. The compound according to claim 9, wherein R^1 , R^2 , R^3 and R^4 are independently selected from hydrogen, methyl, ethyl, fluoro, chloro, cyano and trifluoromethyl.

11. The compound according to claim 10, wherein R^4 is methyl or ethyl and R^1 , R^2 and R^3 are hydrogen.

12. The compound according to claim 10, wherein R^4 is fluoro, cyano or trifluoromethyl and R^1 , R^2 and R^3 are independently selected from hydrogen or methyl.

13. A compound selected from the group consisting of

compounds of formula (I):



wherein

R^1 , R^2 , R^3 and R^4 are independently selected from hydrogen, methyl, ethyl, fluoro, chloro, cyano and trifluoromethyl, with the proviso that at least one of R^1 , R^2 , R^3 and R^4 is not hydrogen;

R^5 is methyl;

R^6 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl or alkoxyalkyl; and

R^7 is hydrogen or methyl;

pharmaceutically acceptable salts of compounds of formula (I);

pharmaceutically acceptable solvates of compounds of formula (I); and

pharmaceutically acceptable esters of compounds of formula (I).


14. The compound according to claim 13, selected from the group consisting of (R)-6-ethyl-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole, pharmaceutically acceptable salts thereof and pharmaceutically acceptable solvates thereof.

15. The compound according to claim 14, which is (R)-6-ethyl-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole.
16. The compound according to claim 13, selected from the group consisting of (R)-4,6-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.
17. The compound according to claim 16, which is (R)-4,6-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole.
18. The compound according to claim 13, selected from the group consisting of (R)-7-chloro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.
19. The compound according to claim 18, which is (R)-7-chloro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole.
20. The compound according to claim 13, selected from the group consisting of (R)-4-methyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.
21. The compound according to claim 20, which is (R)-4-methyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride.
22. The compound according to claim 13, selected from the group consisting of (R)-6-ethyl-8-fluoro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.
23. The compound according to claim 22, which is (R)-6-ethyl-8-fluoro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride.

24. The compound according to claim 13, selected from the group consisting of (R)-8-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.
25. The compound according to claim 24, which is (R)-8-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride.
26. The compound according to claim 13, selected from the group consisting of (R)-6-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.
27. The compound according to claim 26, which is (R)-6-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride.
28. The compound according to claim 13, selected from the group consisting of (R)-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole-6-carbonitrile hydrochloride, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.
29. The compound according to claim 28, which is (R)-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole-6-carbonitrile hydrochloride.
30. The compound according to claim 13, selected from the group consisting of (R)-4,6,10-trimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole oxalate, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.
31. The compound according to claim 30, which is (R)-4,6,10-trimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole oxalate.
32. A compound according to claim 1, selected from the group consisting of (R)-6-thienyl-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;

(R)-4,6-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
 (R)-7-chloro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
 (R)-4-methyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
 (R)-6-ethyl-8-fluoro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
 (R)-8-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
 (R)-6-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
 (R)-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole-6-carbonitrile; and
 (R)-4,6,10-trimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole.

33. A process for the preparation of a compound according to formula (I)



wherein

R^1 , R^2 , R^3 and R^4 are independently selected from hydrogen, halogen, hydroxy, alkyl, cycloalkyl, arylalkyl, aryl, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, nitro, cyano, alkoxycarbonyl, aryloxycarbonyl, mono- and di-alkylaminocarbonyl, alkylcarbonylamino, carboxy and heterocyclyl, or R^3 and R^4 form together a $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ group;

with the proviso that at least one of R^1 , R^2 , R^3 and R^4 is not hydrogen;


R^5 is hydrogen, alkyl or cycloalkyl;

R^6 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl or alkoxyalkyl; and

R^7 is hydrogen, halogen, alkyl, cycloalkyl, hydroxyalkyl, carboxyalkyl, carbamoylalkyl, alkoxycarbonylalkyl, aryloxycarbonylalkyl, formyl, alkylcarbonyl, alkoxy or alkylthio;


comprising alkylation of a compound selected from the group consisting of

a)



wherein R^1 , R^2 , R^3 , R^4 , and R^7 are as defined above,


b)



E

wherein R^1 , R^2 , R^3 , R^4 , R^5 , and R^7 are as defined above, and PG' is hydrogen or an OH-protecting group, and


c)



Z

wherein R^1 , R^2 , R^3 , R^4 , R^5 , and R^7 are as defined above;

with a compound of formula (III)



wherein R^6 is as defined as above.

34. A pharmaceutical composition comprising a compound of formula (I) as set out in claim 1 and a pharmaceutically acceptable carrier or excipient.